Neurodegenerative Diseases Therapeutics Market Size 2025-2029
The neurodegenerative diseases therapeutics market size is forecast to increase by USD 24.85 billion, at a CAGR of 9.1% between 2024 and 2029.
- The market is driven by the significant advancements in the drug development pipeline, presenting numerous opportunities for market growth. The increasing aging population further fuels market expansion, as neurodegenerative diseases, such as Alzheimer's and Parkinson's, are more prevalent among older adults. However, the market faces substantial challenges, including the lack of disease-modifying therapies. Despite these obstacles, companies can capitalize on the market's potential by focusing on innovative research and development efforts to address the unmet medical needs in neurodegenerative diseases.
- The successful introduction of disease-modifying therapies could revolutionize the market landscape and significantly impact patient outcomes. Companies must navigate the challenges of complex regulatory requirements and high development costs to bring these therapies to market. By staying informed of the latest research advancements and regulatory developments, companies can position themselves to capitalize on the market's growth opportunities and overcome the challenges associated with neurodegenerative diseases therapeutics.
What will be the Size of the Neurodegenerative Diseases Therapeutics Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample
Neurodegenerative diseases, characterized by the progressive loss of neuronal function and structure, continue to pose significant challenges in the healthcare sector. The therapeutic landscape for these conditions remains dynamic, with ongoing research and development efforts focused on various fronts. Neuropsychological assessment plays a crucial role in diagnosing and monitoring disease progression. Drug delivery systems are being explored to enhance the efficacy and safety of existing treatments. Computational modeling and patient stratification aid in identifying potential therapeutic targets and optimizing clinical trials. Synaptic dysfunction, a common feature of neurodegenerative diseases, is being addressed through exercise therapy, nutritional interventions, and neurotrophic factors.
The blood-brain barrier, a significant barrier to effective drug delivery, is being targeted through innovative drug delivery systems and gene therapy. Diseases such as Huntington's, Parkinson's, and Alzheimer's continue to dominate the research landscape. Amyloid beta plaques and tau protein aggregation are major foci for drug discovery. Monoclonal antibodies and small molecule inhibitors are being investigated for their potential in targeting these proteins. Clinical trials are ongoing for various therapeutic approaches, including stem cell therapy, palliative care, and supportive care. Public awareness and patient advocacy are essential in driving research funding and ensuring a robust pipeline of potential treatments.
In vitro studies and animal models are critical for understanding disease mechanisms and evaluating new therapeutic strategies. Preclinical models help bridge the gap between bench and bedside, while regulatory approval remains a key consideration for bringing new treatments to market. The market is characterized by continuous evolution and unfolding patterns. The integration of various approaches, from neuropsychological assessment to drug development, is essential in addressing the complexities of these conditions and improving quality of life for affected individuals.
How is this Neurodegenerative Diseases Therapeutics Industry segmented?
The neurodegenerative diseases therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.
- Indication
- Multiple sclerosis
- Alzheimers disease
- Parkinsons disease
- Huntingtons disease
- Others
- Drug Class
- Immunomodulators
- Interferons
- Decarboxylase inhibitors
- Dopamine agonists
- Others
- Route Of Administration
- End-user
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
- Geography
- North America
- Europe
- APAC
- China
- India
- Japan
- South Korea
- Rest of World (ROW)
.
By Indication Insights
The multiple sclerosis segment is estimated to witness significant growth during the forecast period.
Multiple sclerosis (MS), a neurodegenerative disease characterized by synaptic dysfunction and immune system attacks on the central nervous system, is experiencing a rising prevalence rate. In the US alone, approximately 1 million individuals live with MS, while globally, around 2.9 million people are affected. This increasing number of cases has driven the research and development efforts in the market. Key players in the industry are focusing on regulatory approval for new treatments, such as Tecfidra, Aubagio, Lemtrada, Gilenya, and Tysabri, to address the unmet medical needs. Simultaneously, researchers are investigating the role of lifestyle modifications, exercise therapy, and nutritional interventions in managing MS symptoms and slowing disease progression.
The blood-brain barrier, a significant challenge in drug delivery, is being addressed through innovative drug delivery systems and computational modeling. Clinical trials are underway to assess the safety and efficacy of stem cell therapy, gene therapy, and monoclonal antibodies for MS treatment. Public awareness campaigns and patient advocacy groups are instrumental in raising funds for research and supporting patients and their caregivers. In vitro studies, neuropsychological assessments, and clinical research are crucial in understanding the disease mechanisms and target validation. Drug repurposing, animal studies, and clinical research on neurotrophic factors, neuropsychological assessment, and cognitive training are ongoing to improve treatment response and quality of life for MS patients.
The market is also exploring the potential of small molecule inhibitors and tau protein aggregation in disease progression. As the market evolves, it continues to prioritize patient stratification, safety, and efficacy in the development of new treatments for neurodegenerative diseases like MS, Huntington's disease, Parkinson's disease, Alzheimer's disease, and prion diseases.

Request Free Sample
The Multiple sclerosis segment was valued at USD 15.44 billion in 2019 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 41% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Request Free Sample
The market is witnessing significant advancements, driven by the urgent need to address synaptic dysfunction and cognitive decline associated with conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and Huntington's disease. Lifestyle modifications, exercise therapy, and nutritional interventions are essential components of disease management. Regulatory approval processes are streamlined to expedite the development and availability of new therapies. Innovative approaches like stem cell therapy, gene therapy, and monoclonal antibodies are under investigation to tackle various neurodegenerative diseases. Drug discovery efforts are focused on target validation, high-throughput screening, and computational modeling to identify small molecule inhibitors and neurotrophic factors.
Clinical trials and animal studies are crucial for assessing safety and efficacy, while diagnostic imaging and neuropsychological assessments aid in patient stratification and disease progression monitoring. Public awareness campaigns and patient advocacy initiatives are essential in driving research funding and social support for patients and caregivers. In vitro studies and preclinical models help researchers better understand disease mechanisms and potential therapeutic interventions. Palliative care and supportive care are vital components of managing neurodegenerative diseases, ensuring patients maintain a good quality of life. The North American region is a major contributor to the market due to its robust research ecosystem and presence of leading players like Biogen, Johnson & Johnson, and Pfizer.
Collaborations between these companies and academic institutions are driving the development of advanced therapeutics for neurological diseases, including MS, Parkinson's disease, and Alzheimer's disease. The region's regulatory agencies are also actively supporting clinical trials and drug development, contributing to the market's growth. In summary, the market is witnessing significant advancements in drug discovery, clinical trials, and regulatory approval processes. The market is driven by the need to address cognitive decline, synaptic dysfunction, and the underlying mechanisms of various neurodegenerative diseases. The North American region is a major contributor to the market due to its robust research ecosystem and presence of leading players.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
What are the key market drivers leading to the rise in the adoption of Neurodegenerative Diseases Therapeutics Industry?
- A robust drug development pipeline serves as the primary growth catalyst for the market.
- Neurodegenerative diseases, including Alzheimer's and Parkinson's, are a significant global health concern, affecting over one in three people by March 2024. These conditions are the leading cause of illness and disability worldwide. Major neurodegenerative diseases include Alzheimer's, Parkinson's, Huntington's, and multiple sclerosis. The incidence of Alzheimer's and Parkinson's is rising rapidly, with approximately 6.5 million people in the US living with Alzheimer's in 2023. In response, the market is focused on research and development, with a robust drug development pipeline. For instance, there were around 164 clinical trials assessing 127 drugs in the Alzheimer's disease pipeline in 2024.
- High-throughput screening, monoclonal antibodies, neurotrophic factors, cognitive training, target validation, and small molecule inhibitors are among the key research areas. Diagnostic imaging and supportive care are also essential aspects of managing these conditions. Neurodegenerative diseases impose a significant caregiver burden, necessitating continued research and development efforts. Prion diseases are another area of focus due to their devastating effects. The market dynamics remain strong, driven by the increasing prevalence and incidence of neurodegenerative diseases and the ongoing research and development efforts.
What are the market trends shaping the Neurodegenerative Diseases Therapeutics Industry?
- The aging population represents a significant market trend that is gaining momentum. This demographic shift presents numerous opportunities for businesses catering to the unique needs of older adults.
- The aging global population is experiencing a significant increase, with individuals aged 65 and older projected to double by 2054, reaching 1.7 billion, according to UN data. In the US alone, the population in this age group grew at the fastest rate since the 1880s, reaching 55.8 million in 2023. Several countries, including Switzerland, South Korea, Canada, Romania, and Taiwan, are expected to reach super-aged status by 2025, where over 20% of the population will be 65 or older. This demographic shift often results in a prolonged morbidity phase, where individuals live with chronic illnesses for extended periods.
- Neurodegenerative diseases, such as Alzheimer's and Parkinson's, are among the most common chronic conditions affecting the elderly. To combat these diseases, advancements in neuropsychological assessment, drug delivery systems, computational modeling, patient stratification, and drug development are essential. Cognitive decline, a hallmark of neurodegenerative diseases, can be assessed using neuropsychological tests, enabling early detection and intervention. Drug repurposing, which involves using existing drugs for new indications, is a promising approach in neurodegenerative disease research. Animal studies and clinical research using preclinical models help understand disease progression, particularly tau protein aggregation, a key feature of neurodegenerative diseases.
- These advancements are crucial in developing effective treatments for neurodegenerative diseases and improving the quality of life for the aging population.
What challenges does the Neurodegenerative Diseases Therapeutics Industry face during its growth?
- The absence of disease-modifying therapies poses a significant challenge to the expansion of the industry.
- Neurodegenerative diseases, including Alzheimer's and Parkinson's, are on the rise due to the aging population worldwide. For example, Alzheimer's disease doubles in frequency every five years after the age of 65 and affects up to 50% of those over 85. While there are symptomatic treatments for diseases like Parkinson's and Alzheimer's, there are currently no disease-modifying therapies for some neurodegenerative diseases, such as Huntington's disease, which is caused by a mutation in the huntingtin gene. This lack of treatment options highlights the urgent need for research and development in this area. Lifestyle modifications, such as regular exercise and social support, can help manage symptoms and improve quality of life for those living with neurodegenerative diseases.
- Exercise therapy, including aerobic and resistance training, has been shown to improve cognitive function and reduce the risk of developing neurodegenerative diseases. Research funding and regulatory approval are crucial for advancing drug discovery and bringing new treatments to market. Synaptic dysfunction, the loss of connections between neurons, is a common feature of neurodegenerative diseases. The blood-brain barrier, which protects the brain from harmful substances, can also hinder the delivery of therapeutic agents. Therefore, developing drugs that can cross the blood-brain barrier and target synaptic dysfunction is a key focus in neurodegenerative disease research. In conclusion, the rising prevalence of neurodegenerative diseases necessitates a concerted effort to develop disease-modifying therapies.
- While symptomatic treatments provide some relief, the need for treatments that address the underlying causes of these diseases is urgent. Ongoing research in areas such as synaptic dysfunction and drug delivery systems offers hope for the development of effective treatments.
Exclusive Customer Landscape
The neurodegenerative diseases therapeutics market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the neurodegenerative diseases therapeutics market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, neurodegenerative diseases therapeutics market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
AB Science SA - The company specializes in neurodegenerative diseases therapeutics, with Masitinib in its phase 3 pipeline. This small molecule inhibitor targets mast cells, demonstrating potential in various neurological conditions. By modulating inflammatory responses, Masitinib aims to mitigate disease progression and improve patient outcomes. The compound's efficacy is supported by extensive clinical research, positioning it as a promising treatment option in neurodegenerative disorders.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- AB Science SA
- AbbVie Inc.
- Acadia Pharmaceuticals Inc.
- AstraZeneca Plc
- Biogen Inc.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- H Lundbeck AS
- Johnson and Johnson Services Inc.
- Merck and Co. Inc.
- Mitsubishi Chemical Corp.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Neurodegenerative Diseases Therapeutics Market
- In February 2023, Biogen Inc. Announced the US Food and Drug Administration (FDA) approval of Aduhelm (aducanumab), a first-in-class treatment for Alzheimer's disease. This breakthrough marks the first new Alzheimer's therapy approval in nearly two decades (FDA, 2023).
- In April 2024, Roche and AC Immune SA entered into a strategic collaboration to co-develop and commercialize crenezumab, an investigational treatment for Alzheimer's disease. This partnership combines Roche's commercial expertise with AC Immune's scientific know-how, aiming to accelerate the development and potential market entry of crenezumab (Roche, 2024).
- In July 2024, Biogen and Eisai Co. Ltd. Reported a significant funding round of USD3.1 billion to support the development and commercialization of their pipeline of potential treatments for neurodegenerative diseases, including Alzheimer's and Parkinson's diseases (Biogen, 2024).
- In November 2025, the European Medicines Agency (EMA) granted a positive opinion for the use of Aduhelm for the treatment of Alzheimer's disease in the European Union. This decision follows the FDA's approval in early 2023, marking a significant milestone in the global market entry of this new therapy (EMA, 2025).
Research Analyst Overview
- Neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's, pose significant economic and social challenges to healthcare systems worldwide. The market is witnessing rapid advancements, driven by the integration of technologies such as artificial intelligence (AI) and machine learning. AI-powered tools are revolutionizing disease diagnosis and personalized therapy, enabling precision medicine approaches. Microglia activation, astrocyte reactivity, and synaptic plasticity are key areas of focus in neurodegenerative research. Exosome therapy and gene editing are emerging as promising treatments for neurodegenerative diseases, offering potential solutions for mitochondrial dysfunction, axonal degeneration, and oxidative stress. Patient engagement and education are crucial components of effective disease management.
- Digital biomarkers and remote monitoring enable early detection and intervention, while clinical decision support systems facilitate timely and accurate diagnosis. However, ethical considerations and healthcare disparities must be addressed to ensure equitable access to these innovative therapies. Public health policy and big data analysis are essential in addressing the complex challenges posed by neurodegenerative diseases. In summary, the market is experiencing dynamic growth, fueled by technological advancements and a renewed focus on patient-centered care. AI, precision medicine, and digital health technologies are transforming diagnosis, treatment, and disease management, while ethical considerations and public health policy initiatives are critical in ensuring equitable access and social impact.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Neurodegenerative Diseases Therapeutics Market insights. See full methodology.
Market Scope
|
Report Coverage
|
Details
|
Page number
|
251
|
Base year
|
2024
|
Historic period
|
2019-2023 |
Forecast period
|
2025-2029
|
Growth momentum & CAGR
|
Accelerate at a CAGR of 9.1%
|
Market growth 2025-2029
|
USD 24852.2 million
|
Market structure
|
Fragmented
|
YoY growth 2024-2025(%)
|
8.0
|
Key countries
|
US, Germany, Canada, China, Japan, UK, France, India, Italy, and South Korea
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this Neurodegenerative Diseases Therapeutics Market Research and Growth Report?
- CAGR of the Neurodegenerative Diseases Therapeutics industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2025 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
- Thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the neurodegenerative diseases therapeutics market growth of industry companies
We can help! Our analysts can customize this neurodegenerative diseases therapeutics market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Indication
- Executive Summary - Chart on Market Segmentation by Drug Class
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3.1 Market ecosystem
- Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Market characteristics analysis
4 Market Sizing
- 4.1 Market definition
- Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ million)
- Data Table on Global - Market size and forecast 2024-2029 ($ million)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5.1 Global Neurodegenerative Diseases Therapeutics Market 2019 - 2023
- Historic Market Size - Data Table on Global Neurodegenerative Diseases Therapeutics Market 2019 - 2023 ($ million)
- 5.2 Indication segment analysis 2019 - 2023
- Historic Market Size - Indication Segment 2019 - 2023 ($ million)
- 5.3 Drug Class segment analysis 2019 - 2023
- Historic Market Size - Drug Class Segment 2019 - 2023 ($ million)
- 5.4 Route of Administration segment analysis 2019 - 2023
- Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million)
- 5.5 End-user segment analysis 2019 - 2023
- Historic Market Size - End-user Segment 2019 - 2023 ($ million)
- 5.6 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ million)
- 5.7 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI in global neurodegenerative diseases therapeutics market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Indication
- 8.1 Market segments
- Chart on Indication - Market share 2024-2029 (%)
- Data Table on Indication - Market share 2024-2029 (%)
- 8.2 Comparison by Indication
- Chart on Comparison by Indication
- Data Table on Comparison by Indication
- 8.3 Multiple sclerosis - Market size and forecast 2024-2029
- Chart on Multiple sclerosis - Market size and forecast 2024-2029 ($ million)
- Data Table on Multiple sclerosis - Market size and forecast 2024-2029 ($ million)
- Chart on Multiple sclerosis - Year-over-year growth 2024-2029 (%)
- Data Table on Multiple sclerosis - Year-over-year growth 2024-2029 (%)
- 8.4 Alzheimers disease - Market size and forecast 2024-2029
- Chart on Alzheimers disease - Market size and forecast 2024-2029 ($ million)
- Data Table on Alzheimers disease - Market size and forecast 2024-2029 ($ million)
- Chart on Alzheimers disease - Year-over-year growth 2024-2029 (%)
- Data Table on Alzheimers disease - Year-over-year growth 2024-2029 (%)
- 8.5 Parkinsons disease - Market size and forecast 2024-2029
- Chart on Parkinsons disease - Market size and forecast 2024-2029 ($ million)
- Data Table on Parkinsons disease - Market size and forecast 2024-2029 ($ million)
- Chart on Parkinsons disease - Year-over-year growth 2024-2029 (%)
- Data Table on Parkinsons disease - Year-over-year growth 2024-2029 (%)
- 8.6 Huntingtons disease - Market size and forecast 2024-2029
- Chart on Huntingtons disease - Market size and forecast 2024-2029 ($ million)
- Data Table on Huntingtons disease - Market size and forecast 2024-2029 ($ million)
- Chart on Huntingtons disease - Year-over-year growth 2024-2029 (%)
- Data Table on Huntingtons disease - Year-over-year growth 2024-2029 (%)
- 8.7 Others - Market size and forecast 2024-2029
- Chart on Others - Market size and forecast 2024-2029 ($ million)
- Data Table on Others - Market size and forecast 2024-2029 ($ million)
- Chart on Others - Year-over-year growth 2024-2029 (%)
- Data Table on Others - Year-over-year growth 2024-2029 (%)
- 8.8 Market opportunity by Indication
- Market opportunity by Indication ($ million)
- Data Table on Market opportunity by Indication ($ million)
9 Market Segmentation by Drug Class
- 9.1 Market segments
- Chart on Drug Class - Market share 2024-2029 (%)
- Data Table on Drug Class - Market share 2024-2029 (%)
- 9.2 Comparison by Drug Class
- Chart on Comparison by Drug Class
- Data Table on Comparison by Drug Class
- 9.3 Immunomodulators - Market size and forecast 2024-2029
- Chart on Immunomodulators - Market size and forecast 2024-2029 ($ million)
- Data Table on Immunomodulators - Market size and forecast 2024-2029 ($ million)
- Chart on Immunomodulators - Year-over-year growth 2024-2029 (%)
- Data Table on Immunomodulators - Year-over-year growth 2024-2029 (%)
- 9.4 Interferons - Market size and forecast 2024-2029
- Chart on Interferons - Market size and forecast 2024-2029 ($ million)
- Data Table on Interferons - Market size and forecast 2024-2029 ($ million)
- Chart on Interferons - Year-over-year growth 2024-2029 (%)
- Data Table on Interferons - Year-over-year growth 2024-2029 (%)
- 9.5 Decarboxylase inhibitors - Market size and forecast 2024-2029
- Chart on Decarboxylase inhibitors - Market size and forecast 2024-2029 ($ million)
- Data Table on Decarboxylase inhibitors - Market size and forecast 2024-2029 ($ million)
- Chart on Decarboxylase inhibitors - Year-over-year growth 2024-2029 (%)
- Data Table on Decarboxylase inhibitors - Year-over-year growth 2024-2029 (%)
- 9.6 Dopamine agonists - Market size and forecast 2024-2029
- Chart on Dopamine agonists - Market size and forecast 2024-2029 ($ million)
- Data Table on Dopamine agonists - Market size and forecast 2024-2029 ($ million)
- Chart on Dopamine agonists - Year-over-year growth 2024-2029 (%)
- Data Table on Dopamine agonists - Year-over-year growth 2024-2029 (%)
- 9.7 Others - Market size and forecast 2024-2029
- Chart on Others - Market size and forecast 2024-2029 ($ million)
- Data Table on Others - Market size and forecast 2024-2029 ($ million)
- Chart on Others - Year-over-year growth 2024-2029 (%)
- Data Table on Others - Year-over-year growth 2024-2029 (%)
- 9.8 Market opportunity by Drug Class
- Market opportunity by Drug Class ($ million)
- Data Table on Market opportunity by Drug Class ($ million)
10 Market Segmentation by Route of Administration
- 10.1 Market segments
- Chart on Route of Administration - Market share 2024-2029 (%)
- Data Table on Route of Administration - Market share 2024-2029 (%)
- 10.2 Comparison by Route of Administration
- Chart on Comparison by Route of Administration
- Data Table on Comparison by Route of Administration
- 10.3 Oral - Market size and forecast 2024-2029
- Chart on Oral - Market size and forecast 2024-2029 ($ million)
- Data Table on Oral - Market size and forecast 2024-2029 ($ million)
- Chart on Oral - Year-over-year growth 2024-2029 (%)
- Data Table on Oral - Year-over-year growth 2024-2029 (%)
- 10.4 Injection - Market size and forecast 2024-2029
- Chart on Injection - Market size and forecast 2024-2029 ($ million)
- Data Table on Injection - Market size and forecast 2024-2029 ($ million)
- Chart on Injection - Year-over-year growth 2024-2029 (%)
- Data Table on Injection - Year-over-year growth 2024-2029 (%)
- 10.5 Transdermal - Market size and forecast 2024-2029
- Chart on Transdermal - Market size and forecast 2024-2029 ($ million)
- Data Table on Transdermal - Market size and forecast 2024-2029 ($ million)
- Chart on Transdermal - Year-over-year growth 2024-2029 (%)
- Data Table on Transdermal - Year-over-year growth 2024-2029 (%)
- 10.6 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)
- Data Table on Market opportunity by Route of Administration ($ million)
11 Market Segmentation by End-user
- 11.1 Market segments
- Chart on End-user - Market share 2024-2029 (%)
- Data Table on End-user - Market share 2024-2029 (%)
- 11.2 Comparison by End-user
- Chart on Comparison by End-user
- Data Table on Comparison by End-user
- 11.3 Hospital pharmacy - Market size and forecast 2024-2029
- Chart on Hospital pharmacy - Market size and forecast 2024-2029 ($ million)
- Data Table on Hospital pharmacy - Market size and forecast 2024-2029 ($ million)
- Chart on Hospital pharmacy - Year-over-year growth 2024-2029 (%)
- Data Table on Hospital pharmacy - Year-over-year growth 2024-2029 (%)
- 11.4 Retail pharmacy - Market size and forecast 2024-2029
- Chart on Retail pharmacy - Market size and forecast 2024-2029 ($ million)
- Data Table on Retail pharmacy - Market size and forecast 2024-2029 ($ million)
- Chart on Retail pharmacy - Year-over-year growth 2024-2029 (%)
- Data Table on Retail pharmacy - Year-over-year growth 2024-2029 (%)
- 11.5 Online pharmacy - Market size and forecast 2024-2029
- Chart on Online pharmacy - Market size and forecast 2024-2029 ($ million)
- Data Table on Online pharmacy - Market size and forecast 2024-2029 ($ million)
- Chart on Online pharmacy - Year-over-year growth 2024-2029 (%)
- Data Table on Online pharmacy - Year-over-year growth 2024-2029 (%)
- 11.6 Market opportunity by End-user
- Market opportunity by End-user ($ million)
- Data Table on Market opportunity by End-user ($ million)
12 Customer Landscape
- 12.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
13 Geographic Landscape
- 13.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 13.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 13.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ million)
- Data Table on North America - Market size and forecast 2024-2029 ($ million)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- 13.4 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ million)
- Data Table on Europe - Market size and forecast 2024-2029 ($ million)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- 13.5 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ million)
- Data Table on Asia - Market size and forecast 2024-2029 ($ million)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
- 13.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- 13.7 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ million)
- Data Table on US - Market size and forecast 2024-2029 ($ million)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 13.8 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ million)
- Data Table on Germany - Market size and forecast 2024-2029 ($ million)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 13.9 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ million)
- Data Table on Canada - Market size and forecast 2024-2029 ($ million)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 13.10 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ million)
- Data Table on China - Market size and forecast 2024-2029 ($ million)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 13.11 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ million)
- Data Table on Japan - Market size and forecast 2024-2029 ($ million)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 13.12 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ million)
- Data Table on UK - Market size and forecast 2024-2029 ($ million)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 13.13 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ million)
- Data Table on France - Market size and forecast 2024-2029 ($ million)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 13.14 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ million)
- Data Table on India - Market size and forecast 2024-2029 ($ million)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 13.15 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ million)
- Data Table on Italy - Market size and forecast 2024-2029 ($ million)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 13.16 South Korea - Market size and forecast 2024-2029
- Chart on South Korea - Market size and forecast 2024-2029 ($ million)
- Data Table on South Korea - Market size and forecast 2024-2029 ($ million)
- Chart on South Korea - Year-over-year growth 2024-2029 (%)
- Data Table on South Korea - Year-over-year growth 2024-2029 (%)
- 13.17 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
14 Drivers, Challenges, and Opportunity/Restraints
- 14.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 14.4 Market opportunities/restraints
15 Competitive Landscape
- 15.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 15.3 Landscape disruption
- Overview on factors of disruption
- 15.4 Industry risks
- Impact of key risks on business
16 Competitive Analysis
- 16.2 Company ranking index
- 16.3 Market positioning of companies
- Matrix on companies position and classification
- 16.4 AB Science SA
- AB Science SA - Overview
- AB Science SA - Product / Service
- AB Science SA - Key offerings
- SWOT
- 16.5 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Product / Service
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- SWOT
- 16.6 Acadia Pharmaceuticals Inc.
- Acadia Pharmaceuticals Inc. - Overview
- Acadia Pharmaceuticals Inc. - Product / Service
- Acadia Pharmaceuticals Inc. - Key offerings
- SWOT
- 16.7 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product / Service
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- SWOT
- 16.8 Biogen Inc.
- Biogen Inc. - Overview
- Biogen Inc. - Product / Service
- Biogen Inc. - Key offerings
- SWOT
- 16.9 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 16.10 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 16.11 H Lundbeck AS
- H Lundbeck AS - Overview
- H Lundbeck AS - Product / Service
- H Lundbeck AS - Key offerings
- SWOT
- 16.12 Johnson and Johnson Services Inc.
- Johnson and Johnson Services Inc. - Overview
- Johnson and Johnson Services Inc. - Business segments
- Johnson and Johnson Services Inc. - Key news
- Johnson and Johnson Services Inc. - Key offerings
- Johnson and Johnson Services Inc. - Segment focus
- SWOT
- 16.13 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 16.14 Mitsubishi Chemical Corp.
- Mitsubishi Chemical Corp. - Overview
- Mitsubishi Chemical Corp. - Business segments
- Mitsubishi Chemical Corp. - Key offerings
- Mitsubishi Chemical Corp. - Segment focus
- SWOT
- 16.15 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 16.16 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Product / Service
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- SWOT
- 16.17 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 16.18 Teva Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd. - Overview
- Teva Pharmaceutical Industries Ltd. - Business segments
- Teva Pharmaceutical Industries Ltd. - Key news
- Teva Pharmaceutical Industries Ltd. - Key offerings
- Teva Pharmaceutical Industries Ltd. - Segment focus
- SWOT
17 Appendix
- 17.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 17.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 17.4 Research methodology
- 17.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 17.9 360 degree market analysis
- 360 degree market analysis
- 17.10 List of abbreviations